The Science
A platform engineered for tumor selectivity
Patented, monoclonal-antibody-derived therapeutic leads designed to act precisely on cancer cells. All findings below are preclinical and in vitro unless otherwise noted.
The Platform
Multiple modalities, one mission
XFBiologics develops patented, monoclonal-antibody-derived therapeutic leads in partnership with established R&D groups in the US and Canada. The technology platform spans plasmid DNA, fusion proteins, AD5 viral vectors, and stem-cell approaches, generating tumor-selective candidates for cancer and infectious disease.
Mechanism of Action
Bind, sequester, and trigger programmed cell death
An illustrative view of how our fusion-protein candidates are designed to work. Claims are preclinical and mechanistic.
- 1
Selective binding
The fusion-protein candidate selectively binds cancer cells while sparing tested normal-cell controls in preclinical models.
- 2
Lysosomal sequestration
In preclinical models the candidate is sequestered in the lysosome/endosome of the cancer cell.
- 3
Programmed cell death
This is designed to trigger apoptosis and autophagy. Dysfunctional cellular components are degraded via the lysosome and recycled.
On autophagy: dysfunctional cellular components are degraded via the lysosome and recycled, a self-degradation process the candidate is designed to engage alongside apoptosis.
Selectivity
A preclinical signal of selectivity
In the company's preclinical lysosomal-entry assays, the candidate showed high entry into TNBC cell lysosomes, versus a reported 3–10% lysosomal entry for the leading standard-of-care drug.
OTM001 (preclinical assay)
High entry
into TNBC cell lysosomes, in preclinical lysosomal-entry assays.
Leading drug, reported
3–10%
reported lysosomal entry. The leading drug is a >$10B/yr franchise, noted to frame the market, not to claim superiority.
We frame this as a preclinical signal of selectivity, not a claim of clinical superiority.
Preclinical evidence
Tested broadly. Selectivity is the headline
Across in-vitro, 3D, and in-vivo preclinical models. Normal-cell controls showed no cell death.
Tested across breast, bladder, B-cell leukemia, cervical, head & neck, glioblastoma, liver, lung, melanoma, ovarian, and prostate lines (in vitro). Normal breast and liver control cells showed no cell death. Selectivity is the headline.
Relative in-vitro cell death by type (preclinical, illustrative). Normal-cell controls shown in grey.
Delivery
pDNA + lipid nanoparticles
Lipid nanoparticles, the technology behind mRNA COVID-19 vaccines, encapsulate genetic material using cationic lipids, PEGylated lipids, phospholipids, and cholesterol. XFBiologics uses DNA-based LNP delivery for greater stability, lower storage burden, and reduced production cost versus mRNA.
- Cationic lipids: encapsulate the DNA payload
- PEGylated lipids: stability & circulation
- Phospholipids: structural bilayer
- Cholesterol: membrane integrity
Research models
Human-relevant preclinical systems
Organoids
3D stem-cell-derived models that mimic human organs for more accurate preclinical study.
Organs-on-a-chip
Microfluidic devices giving human-organ-specific readouts and reducing reliance on animal testing.
IP & Manufacturing
Protected and production-ready
Intellectual property
Issued 20-year patents (USPTO & EU) plus international PCT coverage.
pDNA manufacturing
Plasmid DNA produced under cGMP.
Fill & finish
Formulation and fill/finish at the company's pilot facility in Singapore.